NCT06313957View on ClinicalTrials.gov

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions
Relapsed B-cell Non-Hodgkin LymphomaRefractory B-cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

LUCAR-20SP cells

Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.

Trial Locations (3)

100070

RECRUITING

Beijing GoBroad Boren Hospital, Beijing

100142

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

collaborator

Beijing Boren Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

lead

Peking University Cancer Hospital & Institute

OTHER